Teachers Retirement System of The State of Kentucky Lowers Position in Catalent, Inc. (NYSE:CTLT)

Teachers Retirement System of The State of Kentucky decreased its stake in Catalent, Inc. (NYSE:CTLT) by 8.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,501 shares of the company’s stock after selling 1,233 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Catalent were worth $817,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Brooklyn Investment Group purchased a new stake in Catalent in the 3rd quarter worth approximately $31,000. Sentry Investment Management LLC bought a new position in shares of Catalent in the third quarter worth approximately $53,000. Longfellow Investment Management Co. LLC increased its stake in shares of Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after purchasing an additional 305 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. raised its position in shares of Catalent by 57.5% during the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock valued at $72,000 after purchasing an additional 431 shares during the period. Finally, Intact Investment Management Inc. bought a new stake in shares of Catalent during the 3rd quarter valued at $73,000.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. StockNews.com downgraded shares of Catalent from a “hold” rating to a “sell” rating in a report on Tuesday, December 10th. Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Robert W. Baird reissued a “neutral” rating and set a $63.50 target price on shares of Catalent in a research note on Tuesday, September 24th. Finally, William Blair restated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating and seven have given a hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $63.40.

Catalent Stock Performance

Shares of CTLT stock opened at $63.48 on Thursday. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The stock has a market capitalization of $11.52 billion, a price-to-earnings ratio of -28.09, a price-to-earnings-growth ratio of 2.70 and a beta of 1.15. Catalent, Inc. has a 12-month low of $41.15 and a 12-month high of $63.50. The stock’s 50-day moving average price is $60.41 and its 200-day moving average price is $59.18.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business’s revenue was up 4.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.10) EPS. Equities research analysts predict that Catalent, Inc. will post 0.78 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now directly owns 36,304 shares in the company, valued at $2,177,150.88. The trade was a 5.21 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the sale, the director now owns 10,835 shares in the company, valued at $646,849.50. This represents a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,114 shares of company stock worth $305,931. Insiders own 0.31% of the company’s stock.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.